Tom 16, Nr 4 (2023)
Artykuł przeglądowy
Opublikowany online: 2024-02-09
Wyświetlenia strony
203
Wyświetlenia/pobrania artykułu
127
Trombofilia a niedokrwienny udar mózgu
DOI: 10.5603/jtm.98789
Journal of Transfusion Medicine 2023;16(4):253-259.
Streszczenie
Niedokrwienny udar mózgu najczęściej jest spowodowany zmianami miażdżycowymi w domózgowych naczyniach tętniczych lub zatorowością w przebiegu zaburzeń rytmu serca. W rzadszych przypadkach, szczególnie u ludzi młodych, może jednak wiązać się ze stanami nadkrzepliwości krwi. Wykrycie współistnienia trombofilii wymaga specjalistycznej diagnostyki i w pewnych przypadkach wpływa zasadniczo na postępowanie z chorym. Wykrycie trombofilii może wpływać na decyzję o zabiegowym zamknięciu przetrwałego otworu owalnego u chorych po przebytym udarze niedokrwiennym mózgu, natomiast wykrycie zespołu antyfosfolipidowego wpływa istotnie na wybór leczenia przeciwzakrzepowego w ramach wtórnej prewencji udaru.
Słowa kluczowe: niedokrwienny udar mózguwrodzona trombofiliazespół antyfosfolipidowyprzetrwały otwór owalny
Referencje
- Zawilska K. Trombofilia wrodzona. W: Zakrzepy i Zatory, pod red. Windyga J, Pasierski T, Torbicki A. PZWL, Warszawa, 2014. Str : 53–68.
- EGEBERG O. THROMBOPHILIA CAUSED BY INHERITABLE DEFICIENCY OF BLOOD ANTITHROMBIN. Scand J Clin Lab Invest. 1965; 17: 92.
- Musiał J. Zespół antyfosfolipidowy. W: Zakrzepy i Zatory, pod red. Windyga J, Pasierski T, Torbicki A. PZWL , Warszawa, Str : 69–84.
- Cervera R, Piette J, Font J, et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis & Rheumatism. 2002; 46(4): 1019–1027.
- World Health Organization. The top 10 causes of death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
- Adamson J, Beswick A, Ebrahim S. Is stroke the most common cause of disability? J Stroke Cerebrovasc Dis. 2004; 13(4): 171–177.
- Niewada M, Członkowska A. Zakrzepy i zatory tętnic mózgowych. W: Zakrzepy i Zatory, pod red. Windyga J, Pasierski T, Torbicki A. PZWL , Warszawa : 347–369.
- Yaghi S, Bernstein R, Passman R, et al. Cryptogenic Stroke. Circul Res. 2017; 120(3): 527–540.
- Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995; 332(14): 912–917.
- Hamedani AG, Cole JW, Mitchell BD, et al. Meta-analysis of factor V Leiden and ischemic stroke in young adults: the importance of case ascertainment. Stroke. 2010; 41(8): 1599–1603.
- Jiang B, Ryan KA, Hamedani A, et al. Prothrombin G20210A mutation is associated with young-onset stroke: the genetics of early-onset stroke study and meta-analysis. Stroke. 2014; 45(4): 961–967.
- Chiasakul T, De Jesus E, Tong J, et al. Inherited Thrombophilia and the Risk of Arterial Ischemic Stroke: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2019; 8(19): e012877.
- Majmundar S, Thapa S, Miller ES, et al. Low value of inherited thrombophilia testing among patients with stroke or transient ischemic attack: A three-year retrospective study. J Stroke Cerebrovasc Dis. 2023; 32(10): 107308.
- Swan D, Connors JM, Thachil J. Dilemmas in hematology: consults in patients with arterial thrombosis. J Thromb Haemost. 2023; 21(3): 421–432.
- Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984; 59(1): 17–20.
- Thaler DE, Di Angelantonio E, Di Tullio MR, et al. The risk of paradoxical embolism (RoPE) study: initial description of the completed database. Int J Stroke. 2013; 8(8): 612–619.
- Messé S, Gronseth G, Kent D, et al. Practice advisory update summary: Patent foramen ovale and secondary stroke prevention. Neurology. 2020; 94(20): 876–885.
- Kavinsky C, Szerlip M, Goldsweig A, et al. SCAI Guidelines for the Management of Patent Foramen Ovale. Journal of the Society for Cardiovascular Angiography & Interventions. 2022; 1(4): 100039.
- Turc G, Calvet D, Guérin P, et al. CLOSE Investigators. Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study. J Am Heart Assoc. 2018; 7(12).
- Hviid CVB, Simonsen CZ, Hvas AM. Recurrence Risk in Patients with Cryptogenic Stroke, Patent Foramen Ovale, and Thrombophilia: A Systematic Review and Meta-Analysis. Thromb Haemost. 2019; 119(11): 1839–1848.
- Farjat-Pasos JI, Nuche J, Mesnier J, et al. Transcatheter Patent Foramen Ovale Closure in Stroke Patients with Thrombophilia: Current Status and Future Perspectives. J Stroke. 2022; 24(3): 335–344.
- Geisler T, Keller T, Martus P, et al. Apixaban versus aspirin for embolic stroke of undetermined source. NEJM Evid. 2023; 3(1).
- Pristipino C, Sievert H, D’Ascenzo F, et al. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. Eur Heart J. 2018; 40(38): 3182–3195.
- Dębski M, Abdelrahman A, Alshehri H, et al. Contemporary Management of Patent Foramen Ovale: A Multinational Survey on Cardiologists' Perspective. J Interv Cardiol. 2021; 2021: 6955791.
- Barbhaiya M, Zuily S, Naden R, et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2023; 82(10): 1258–1270.
- Cohen H, Werring D, Chandratheva A, et al. Survey on antiphospholipid syndrome diagnosis and antithrombotic treatment in patients with ischemic stroke, other brain ischemic injury, or arterial thromboembolism in other sites: communication from ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. J Thromb Haemost. 2023; 21(10): 2963–2976.
- Sciascia S, Sanna G, Khamashta MA, et al. APS Action. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. Ann Rheum Dis. 2015; 74(11): 2028–2033.
- Mittal P, Quattrocchi G, Tohidi-Esfahani I, et al. Antiphospholipid syndrome, antiphospholipid antibodies, and stroke. Int J Stroke. 2023; 18(4): 383–391.
- Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011; 118(17): 4714–4718.
- Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010; 8(2): 237–242.
- Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019; 78(10): 1296–1304.
- Vreede AP, Bockenstedt PL, McCune WJ, et al. Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome. Curr Opin Rheumatol. 2019; 31(3): 231–240.
- Devreese KMJ, de Groot PG, de Laat B, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost. 2020; 18(11): 2828–2839.
- Zuily S, Clerc-Urmès I, Bauman C, et al. APS ACTION Investigators. Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. Lupus. 2020; 29(11): 1353–1363.
- Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018; 132(13): 1365–1371.
- Zuily S, Cohen H, Isenberg D, et al. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020; 18(9): 2126–2137.
- Giarretta I, Ageno W, Dentali F. Lack of efficacy of direct oral anticoagulants compared to warfarin in antiphospholipid antibody syndrome. Haematologica. 2022; 107(11): 2737–2741.
- Khairani CD, Bejjani A, Piazza G, et al. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2023; 81(1): 16–30.
- Crowther MA, Jones AE, Witt DM. Warfarin Is the Preferred Therapy for Patients With Thrombotic APS: Back to the Future. J Am Coll Cardiol. 2023; 81(1): 31–33.
- Hart R, Catanese L, Perera K, et al. Embolic Stroke of Undetermined Source. Stroke. 2017; 48(4): 867–872.
